General Information of Drug (ID: DMXW92T)

Drug Name
Ixekizumab
Synonyms LY2439821
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Approved [1]
Psoriatic arthritis FA21 Phase 3 [2]
Drug Type
Monoclonal antibody
Sequence
>heavy chain
QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDY
NQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSA
STKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGN
VFSCSVMHEALHNHYTQKSLSLSLG
>light chain
DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRF
IGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIKRTVAAPSV
FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL
SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 16.2 +/- 6.6 mg/L []
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4 h []
Clearance
The clearance of drug is 0.39 L/day []
Half-life
The concentration or amount of drug in body reduced by one-half in 13 days [3]
Metabolism
The drug is metabolized via the catabolic pathways in the same manner as endogenous IgG []
Vd
The volume of distribution (Vd) of drug is 7.11 L []
Cross-matching ID
DrugBank ID
DB11569
TTD ID
D08NMV
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Modulator [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Plaque psoriasis
ICD Disease Classification EA90.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-17 (IL17) DTT IL17A 2.91E-02 -0.16 -0.69
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ixekizumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Moderate Altered metabolism of Ixekizumab due to Oliceridine alters the formation of CYP450 enzymes. Acute pain [MG31] [5]
Lurbinectedin DMEFRTZ Moderate Additive myelosuppressive effects by the combination of Ixekizumab and Lurbinectedin. Lung cancer [2C25] [5]
GDC-0199 DMH0QKA Moderate Altered metabolism of Ixekizumab due to GDC-0199 alters the formation of CYP450 enzymes. Mature B-cell leukaemia [2A82] [5]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Ixekizumab and Siponimod. Multiple sclerosis [8A40] [6]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Ixekizumab and Ocrelizumab. Multiple sclerosis [8A40] [7]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Ixekizumab and Ozanimod. Multiple sclerosis [8A40] [5]
⏷ Show the Full List of 6 DDI Information of This Drug

References

1 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7541).
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
5 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6 Cerner Multum, Inc. "Australian Product Information.".
7 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.